572 related articles for article (PubMed ID: 34685739)
1. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression.
Caligiuri A; Gentilini A; Pastore M; Gitto S; Marra F
Cells; 2021 Oct; 10(10):. PubMed ID: 34685739
[TBL] [Abstract][Full Text] [Related]
2. Resolution of organ fibrosis.
Jun JI; Lau LF
J Clin Invest; 2018 Jan; 128(1):97-107. PubMed ID: 29293097
[TBL] [Abstract][Full Text] [Related]
3. Molecular interplays in hepatic stellate cells: apoptosis, senescence, and phenotype reversion as cellular connections that modulate liver fibrosis.
de Oliveira da Silva B; Ramos LF; Moraes KCM
Cell Biol Int; 2017 Sep; 41(9):946-959. PubMed ID: 28498509
[TBL] [Abstract][Full Text] [Related]
4. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.
Iwaisako K; Brenner DA; Kisseleva T
J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):65-8. PubMed ID: 22320919
[TBL] [Abstract][Full Text] [Related]
5. Recent advancement of molecular mechanisms of liver fibrosis.
Seki E; Brenner DA
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):512-8. PubMed ID: 25869468
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular mechanisms of liver fibrosis and its regression.
Kisseleva T; Brenner D
Nat Rev Gastroenterol Hepatol; 2021 Mar; 18(3):151-166. PubMed ID: 33128017
[TBL] [Abstract][Full Text] [Related]
7. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis.
Mallat A; Lotersztajn S
Am J Physiol Cell Physiol; 2013 Oct; 305(8):C789-99. PubMed ID: 23903700
[TBL] [Abstract][Full Text] [Related]
8. The Origin and Fate of Liver Myofibroblasts.
Kim HY; Sakane S; Eguileor A; Carvalho Gontijo Weber R; Lee W; Liu X; Lam K; Ishizuka K; Rosenthal SB; Diggle K; Brenner DA; Kisseleva T
Cell Mol Gastroenterol Hepatol; 2024; 17(1):93-106. PubMed ID: 37743012
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of liver fibrosis.
Sun M; Kisseleva T
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(0 1):S60-3. PubMed ID: 26206574
[TBL] [Abstract][Full Text] [Related]
10. Anti-fibrogenic strategies and the regression of fibrosis.
Kisseleva T; Brenner DA
Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):305-17. PubMed ID: 21497747
[TBL] [Abstract][Full Text] [Related]
11. Partial hepatectomy-induced regeneration accelerates reversion of liver fibrosis involving participation of hepatic stellate cells.
Suárez-Cuenca JA; Chagoya de Sánchez V; Aranda-Fraustro A; Sánchez-Sevilla L; Martínez-Pérez L; Hernández-Muñoz R
Exp Biol Med (Maywood); 2008 Jul; 233(7):827-39. PubMed ID: 18445764
[TBL] [Abstract][Full Text] [Related]
12. EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells.
Mimche PN; Lee CM; Mimche SM; Thapa M; Grakoui A; Henkemeyer M; Lamb TJ
Sci Rep; 2018 Feb; 8(1):2532. PubMed ID: 29416088
[TBL] [Abstract][Full Text] [Related]
13. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.
Xu J; Liu X; Koyama Y; Wang P; Lan T; Kim IG; Kim IH; Ma HY; Kisseleva T
Front Pharmacol; 2014; 5():167. PubMed ID: 25100997
[TBL] [Abstract][Full Text] [Related]
14. The origin of fibrogenic myofibroblasts in fibrotic liver.
Kisseleva T
Hepatology; 2017 Mar; 65(3):1039-1043. PubMed ID: 27859502
[TBL] [Abstract][Full Text] [Related]
15. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.
Chen RJ; Wu HH; Wang YJ
Arch Toxicol; 2015 Oct; 89(10):1727-50. PubMed ID: 25963329
[TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.
Elpek GÖ
World J Gastroenterol; 2014 Jun; 20(23):7260-76. PubMed ID: 24966597
[TBL] [Abstract][Full Text] [Related]
17. New therapies for hepatic fibrosis.
Koyama Y; Brenner DA
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(0 1):S75-9. PubMed ID: 26206573
[TBL] [Abstract][Full Text] [Related]
18. New Developments on the Treatment of Liver Fibrosis.
Koyama Y; Xu J; Liu X; Brenner DA
Dig Dis; 2016; 34(5):589-96. PubMed ID: 27332862
[TBL] [Abstract][Full Text] [Related]
19. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.
Kisseleva T; Cong M; Paik Y; Scholten D; Jiang C; Benner C; Iwaisako K; Moore-Morris T; Scott B; Tsukamoto H; Evans SM; Dillmann W; Glass CK; Brenner DA
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9448-53. PubMed ID: 22566629
[TBL] [Abstract][Full Text] [Related]
20. Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential.
Kong D; Zhang F; Zhang Z; Lu Y; Zheng S
Biomed Pharmacother; 2013 Apr; 67(3):246-50. PubMed ID: 23201010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
